#ESMO26 @AndreaNecchi presented ENERGIZE (CA017-078), comparing perioperative nivolumab + gemcitabine/cisplatin vs GC alone (N=653).
🔹 pCR: 39.1% vs 29.6%, but statistical threshold not met
🔹 EFS: HR 0.94; p=0.67
🔹 OS: HR 0.88 (descriptive)
🔹 Grade ≥3 AEs: 73% vs 56%
🧬 ctDNA clearance was strongly prognostic for EFS and OS, but neither baseline ctDNA status nor clearance identified patients who benefited more from nivolumab.
@UroToday @myESMO
304 浏览 · 4 赞 · 4 转发 · 0 回复
Emotional distress (ED) upfront neoadjuvant ipilimumab + nivolumab (IPI+NIVO) is associated with lower pathological response and toxicity
https://esmocongress.esmo.orgResults from a phase 3 trial of neoadjuvant (neoadj) chemotherapy alone vs in combination with nivolumab followed by postsurgical adjuvant nivolumab in patients (pts) with muscle-invasive bladder cancer (MIBC)
https://esmocongress.esmo.orgFinal pathological and radiological outcomes and initial EFS from a blinded, exploratory phase 2 trial of nivolumab ± visugromab in MIBC (GDFather-NEO)
https://esmocongress.esmo.orgPrimary analysis of HBI-8000-303: A randomized phase 3 trial of nivolumab plus HBI-8000 or placebo in advanced melanoma
https://esmocongress.esmo.org- **标题 / Title：** Efficacy of Tedopi Plus Docetaxel or Tedopi Plus Nivolumab as Second-line Therapy in Metastatic Non-small-cell Lung Cancer Progressing After First-line Chemo-immunotherapy (Combi-TED)
https://esmocongress.esmo.org来源：Julian Chavarriaga · x.com